Immune Therapy’s Cancer Promise Creates Research Rush
This article is for subscribers only.
A new class of medicines that help the body’s own immune cells fight tumors could target a wide set of cancers, opening a $35 billion market for Merck & Co., Bristol-Myers Squibb Co., AstraZeneca Plc and Roche Holding AG.
The drugmakers will use the world’s largest meeting of cancer doctors, the American Society of Clinical Oncology, to stake their claim on the new technology, which aims to interrupt cancer’s ability to switch off immune system cells that might otherwise attack it.